Corbus Pharmaceuticals Holdings, Inc. (CRBP) analyst actions
Rating and price-target actions on CRBP in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CRBP overview →
1 measured CRBP analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | Press release | -1.91% | -5.74% |
Keep exploring
More CRBP: earnings → · SEC filings → · CRBP overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 306 | +0.04% | 51% |
| U.S. Physical Therapy, Inc. (USPH) | 304 | -0.03% | 46% |
| The Cooper Companies, Inc. (COO) | 303 | -0.21% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.